natgillin/translations-raw huggingface dataset:
It was to be available as a syringe containing a liquid for drinking, containing the active substance 1-13C-caprylic acid (90 mg). 
Zdravilo naj bi bilo na voljo v obliki injekcijske brizge, ki vsebuje pitno tekočino z zdravilno učinkovino 1-13C-kaprilno kislino (90 mg).
The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with Gastromotal. 
Podjetje je CHMP obvestilo, da za bolnike, ki so trenutno vključeni v klinična preizkušanja ali sočutno uporabo zdravila Gastromotal, ni nobenih posledic.
Based on the review of the data and the company's response to the CHMP list of questions at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Gastromotal could not have been approved for the diagnosis of delayed stomach emptying. 
Na podlagi pregleda podatkov in odgovorov podjetja na seznam vprašanj, ki jih je zastavil CHMP, je imel Odbor v času umika vloge zadržke in bil začasnega mnenja, da za zdravilo Gastromotal ni mogoče odobriti dovoljenja za diagnozo upočasnjenega praznjenja želodca.
Gastromotal was expected to be used to diagnose delayed stomach emptying in patients with stomach problems. 
Zdravilo Gastromotal naj bi se uporabljalo za diagnozo upočasnjenega praznjenja želodca pri bolnikih z želodčnimi težavami.
The CHMP was concerned that the reliability and usefulness of Gastromotal in diagnosing delayed stomach empting had not been shown. 
CHMP je izrazil zadržke, ker zanesljivost in uporabnost zdravila Gastromotal pri diagnostiki upočasnjenega praznjenja želodca nista bili dokazani.
What is Gastromotal? 
Kaj je zdravilo Gastromotal?
What was Gastromotal expected to be used for? 
Za kaj naj bi se zdravilo Gastromotal uporabljalo?
The effectiveness of Gastromotal has been compared with that of a standard test called 99Tc-scintigraphy (a type of scan using radioactive tracers) in two main studies involving a total of 310 
Učinkovitost zdravila Gastromotal so primerjali s standardnim testom, imenovanim 99Tc-scintigrafija
The CHMP was assessing the responses given by the company to a list of questions. 
Podjetje je umaknilo vlogo na 200. dan. CHMP je ocenil odgovore podjetja na seznam vprašanj.
How is Gastromotal expected to work? 
Kako naj bi zdravilo Gastromotal delovalo?
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the Member States 
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe, imetnikov dovoljenja za promet z zdravilom v državah članicah
D-85540 Haar 
D-85540 Haar Nemčija
Šmartinska cesta 140, 1000 Ljubljana, Slovenia 
Šmartinska cesta 140, 1000 Ljubljana, Slovenija
Powder for suspension for parenteral use (IM) 
prašek za suspenzijo za parenterlano uporabo (i.m.)
Bucureşti-Ploieşti Nr.1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti 
Bucureşti-Ploieşti Nr.1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti, Romuija
18th Km Athens-Lamia National Road 14671 Nea Erythrea Greece 
18th Km Athens-Lamia National Road 14671 Nea Erythrea Grčija
C/ Josefa Valcárcel, 38 28027 Madrid Spain 
C/ Josefa Valcárcel, 38 28027 Madrid Španija
Via Vitorchiano, 151 - 00189 Roma 
Via Vitorchiano, 15100189 Roma Italija
Hertford Road, Hoddesdon, Hertfordshire EN11 9BU United Kingdom 
Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Združeno kraljestvo Velike Britanije in Severne Irske
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Herts, EN11 9BU United Kingdom 
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Herts, EN11 9BU, Združeno kraljestvo Velike Britanije in Severne Irske
Dry Powder for injection 
suhi prašek za injekcije intravenska uporaba
Merck Sharp & Dohme, UAB, Kęstučio 59/27, LT-08124 Vilnius 
Kęstučio 59/27, LT-08124 Vilnius,
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A, Viale Shakespeare, 47 00144 Roma 
Viale Shakespeare, 47 00144 Roma Italija
Merck Sharp & Dohme B.V. Waarderweg 39, 2031 BN Haarlem, P.O.Box 581, 2003 PC Haarlem 
Waarderweg 39, 2031 BN Haarlem, P.O.Box 581, 2003 PC Haarlem Nizozemska
Merck Sharp & Dohme B.V. Waarderweg 39, Haarlem, P.O.Box 581, 2003 PC Haarlem The Netherlands 
Waarderweg 39, Haarlem, P.O.Box 581, 2003 PC Haarlem Nizozemska
250 mg/250 mg Powder for infusion 
250 mg/250 mg prašek za infundiranje intravenska uporaba
500 mg powder for solution for infusion 500 mg/500 mg Powder for solution for infusion Intravenous use 
500 mg powder for solution for infusion 500 mg/500 mg prašek za raztopino za infundiranje
ZIENAM° 500 mg Pulver zur Herstellung einer Infusionslösung 
ZIENAM° 500 mg Pulver zur Herstellung einer Infusionslösung intravenska iuporaba
Merck Sharp & Dohme B.V. Waarderweg 39, 2031 BN Haarlem, The Netherlands 
Waarderweg 39, 2031 BN Haarlem, Nizozemska
500 mg/500 mg 
250 mg in 500 mg
PrimaxinIV 500mg Injection 500mg 
PrimaxinIV 500mg Injection 500mg prašek za koncentrat za raztopino za infundiranje
Primaxin IV 500mg Injection 500mg 
Primaxin IV 500mg Injection 500mg prašek za koncentrat za raztopino za infundiranje
500 mg/500 mg Powder for infusion 
500 MG/500 MG 500 mg/500 mg prašek za raztopino za infundiranje
500 mg + 500 mg Powder for solution for injection Intravenous use 
500 mg/500 mg prašek za infundiranje intravenska uporaba
Further information on Keytruda can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/keytruda. 
Nadaljnje informacije za zdravilo Keytruda so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/keytruda.
The European Medicines Agency decided that Keytruda's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Keytruda večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Keytruda received a marketing authorisation valid throughout the EU on 17 July 2015. 
Za zdravilo Keytruda je bilo 17. julija 2015 izdano dovoljenje za promet, veljavno po vsej EU.
What measures are being taken to ensure the safe and effective use of Keytruda? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Keytruda?
In addition, the company will provide the final results of studies with Keytruda to confirm the longterm benefits of the medicine. 
Poleg tega bo predložilo tudi končne rezultate študij o zdravilu Keytruda, ki naj bi potrdili dolgoročne koristi tega zdravila.
Moreover, the company will carry out analyses to better understand which patients are likely to benefit most from treatment with Keytruda. 
Prav tako bo opravilo analize, da bi bolje razumeli, kateri bolniki bi lahko imeli največ koristi od zdravljenja z zdravilom Keytruda.
When it is given with other cancer medicines, the dose is always 200 mg every three weeks. 
Kadar se daje v kombinaciji z drugimi zdravili za zdravljenje raka, znaša odmerek vedno 200 mg vsake tri tedne.
The medicine can only be obtained with a prescription and treatment must be started and supervised by a doctor experienced in the treatment of cancer. 
Predpisovanje in izdaja zdravila je le na recept, zdravljenje pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem rakavih obolenj.
Why is Keytruda authorised in the EU? 
Zakaj je bilo zdravilo Keytruda odobreno v EU?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Keytruda have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Keytruda upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What benefits of Keytruda have been shown in studies? 
Kakšne koristi zdravila Keytruda so se pokazale v študijah?
As for all medicines, data on the use of Keytruda are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Keytruda stalno spremljajo.
The company that markets Keytruda will provide patients with an information pack and alert card to inform them about the risks of potential immune-related side effects and give instructions on when to contact their doctor if they experience symptoms. 
Podjetje, ki trži zdravilo Keytruda, bo bolnikom priskrbelo informativni bilten in opozorilno kartico z obvestilom o tveganjih neželenih učinkov na imunski sistem in navodili za posvetovanje z zdravnikom v primeru pojava simptomov.
An overview of Keytruda and why it is authorised in the EU 
Pregled zdravila Keytruda in zakaj je odobreno v EU
Side effects reported with Keytruda are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Keytruda, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
When Keytruda is given alone the dose is either 200 mg every three weeks or 400 mg every six weeks. 
Kadar se zdravilo Keytruda daje kot samostojno zdravilo, znaša odmerek bodisi 200 mg vsake tri tedne bodisi 400 mg vsakih šest tednov.
What is Keytruda and what is it used for? 
Kaj je zdravilo Keytruda in za kaj se uporablja?
The average time that patients lived without their disease getting worse again was around 11 months. 
Povprečno trajanje obdobja brez ponovnega poslabšanja bolezni je bilo okoli enajst mesecev.
Keytruda is mainly used for cancers that are advanced, have spread to other parts of the body (metastatic) or are not responding to other treatments. 
Zdravilo Keytruda se uporablja predvsem pri tistih rakavih obolenjih, ki so napredovala, se razširila na druge dele telesa (so metastatska) ali se ne odzivajo na druga zdravila.
Other information about Keytruda 
Druge informacije o zdravilu Keytruda
For more information about using Keytruda, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Keytruda glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with Keytruda? 
Kakšna tveganja so povezana z zdravilom Keytruda?
Keytruda did not delay worsening of the disease compared with the other cancer medicines (time to disease worsening was 2 and 3 months respectively). 
Zdravilo Keytruda ni upočasnilo poslabšanja bolezni v primerjavi z drugimi zdravili za zdravljenje raka (čas do poslabšanja bolezni je bil dva oziroma tri mesece).
The most common side effects of Keytruda given alone (which may affect more than 1 in 5 people) are tiredness, nausea (feeling sick) and diarrhoea. 
Najpogostejši neželeni učinki zdravila Keytruda (ki se lahko pojavijo pri več kot 1 bolniku od 5) so utrujenost, navzeja (siljenje na bruhanje) in driska.
At 18 months, 81% of the patients given the combination were alive, compared with 71% in the sunitinib group. 
Po 18 mesecih je bilo 81 % bolnikov, ki so prejemali kombinacijo zdravil, še vedno živih, v primerjavi z 71 % tistih, ki so prejemali sunitinib.
Some cancers can make a protein (PD-L1) that combines with PD-1 to switch off the activity of certain cells of the immune system (the body's natural defences) preventing them from attacking the cancer. 
Nekatere vrste rakavih obolenj lahko povzročijo, da beljakovina (PD-L1), ki se veže na receptor PD-1, prekine dejavnost določenih celic imunskega sistema (naravnega obrambnega mehanizma telesa), s čimer jim prepreči napadanje rakavih celic.
The active substance in Keytruda, pembrolizumab, is a monoclonal antibody, a protein that has been designed to recognise and block a receptor (‘target') called PD-1. 
Učinkovina zdravila Keytruda, pembrolizumab, je monoklonsko protitelo, tj. beljakovina, ki je bila zasnovana tako, da prepozna in zavre receptor (prijemališče), imenovan PD-1.
Keytruda can delay worsening of melanoma and improve survival. 
Zdravilo Keytruda lahko upočasni slabšanje melanoma in podaljša preživetje.
Keytruda is also effective in combination treatment of a type of NSCLC known as ‘non-squamous' cancer, based on the type of cancer cells involved. 
Zdravilo Keytruda je učinkovito tudi pri kombiniranem zdravljenju vrste nedrobnoceličnega pljučnega raka, znanega kot „neploščatocelični“ rak, glede na vrsto prisotnih rakavih celic.
The side effects with this medicine are manageable and are similar to those of various other cancer treatments. 
Neželeni učinki tega zdravila so obvladljivi in podobni neželenim učinkom, ki se pojavljajo pri številnih drugih zdravilih za zdravljenje raka.
A second study looked at 834 patients with melanoma who received either Keytruda or another medicine, ipilimumab. 
V drugi študiji so proučevali 834 bolnikov z melanomom, ki so prejemali zdravilo Keytruda ali drugo zdravilo, ipilimumab.
The doctor may delay doses if certain side effects occur or stop treatment altogether if side effects are severe. 
Če se pojavijo nekateri neželeni učinki, bo zdravnik morda odložil nadaljnje odmerke ali popolnoma prekinil zdravljenje, če so neželeni učinki resni.
Results from a study of 540 previously treated patients with melanoma showed that 2 years after start of treatment, the disease had not worsened in 16% of patients treated with Keytruda compared with less than 1% of patients treated with chemotherapy. 
Rezultati študije pri 540 predhodno zdravljenih bolnikih z melanomom so pokazali, da se dve leti po začetku zdravljenja bolezen ni poslabšala pri 16 % bolnikov, zdravljenih z zdravilom Keytruda, v primerjavi z manj kot 1 % bolnikov, zdravljenih s kemoterapijo.
By blocking PD-1, pembrolizumab stops the cancer switching off these immune cells, thereby increasing the immune system's ability to kill the cancer cells. 
Pembrolizumab z zaviranjem receptorja PD-1 prepreči raku, da bi ta prekinil delovanje navedenih imunskih celic, s čimer poveča sposobnost imunskega sistema za uničevanje rakavih celic.
A study looked at 542 patients previously treated with platinum-based medicines who received either Keytruda or another cancer medicine chosen by the doctor (paclitaxel, docetaxel or vinflunine). 
V študiji so proučevali 542 bolnikov, ki so se že zdravili z zdravili na osnovi platine in so prejemali zdravilo Keytruda ali drugo zdravilo za zdravljenje raka po izboru zdravnika (paklitaksel, docetaksel ali vinflunin).
For renal cell carcinoma, Keytruda is used in combination with other cancer medicines. 
Pri zdravljenju raka ledvičnih celic se zdravilo Keytruda uporablja v kombinaciji z drugimi zdravili za zdravljenje raka.
A third study in 1,019 patients who had had surgery and who were at high risk for their cancer coming back compared Keytruda to placebo (a dummy treatment). 
V tretji študiji, v katero je bilo vključenih 1 019 bolnikov, ki so imeli kirurški poseg in so bili izpostavljeni visokemu tveganju za ponovitev raka, so zdravilo Keytruda primerjali s placebom (zdravilom brez učinkovine).
Keytruda is also used to help prevent the cancer from coming back after patients had surgery to remove melanoma (adjuvant therapy). 
Zdravilo Keytruda se uporablja tudi za preprečevanje ponovitve raka, potem ko je bil pri bolniku opravljen kirurški poseg odstranitve melanoma (adjuvantno zdravljenje).
For the full list of side effects and restrictions with Keytruda, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Keytruda glejte navodilo za uporabo.
After one and a half years of treatment, 72% of patients on Keytruda were still disease-free compared with 54% of patients on placebo. 
Po enem letu in pol zdravljenja še vedno ni bilo znakov bolezni pri 72 % bolnikov, ki so prejemali zdravilo Keytruda, v primerjavi s 54 % bolnikov, ki so prejemali placebo.
Skin cancer 
Kožni rak
In a further study of 559 patients with ‘squamous' NSCLC that had spread, patients given Keytruda with carboplatin and paclitaxel or nab-paclitaxel lived on average for 15.9 months compared with 11.3 months for patients given placebo with carboplatin and paclitaxel or nab-paclitaxel. 
V nadaljnji študiji, v kateri je sodelovalo 559 bolnikov s ploščatoceličnim nedrobnoceličnim pljučnim rakom, ki se je razširil, so bolniki, ki so prejemali zdravilo Keytruda v kombinaciji s karboplatinom in paklitakselom ali nabpaklitakselom, v povprečju živeli 15,9 meseca v primerjavi z 11,3 meseca pri bolnikih, ki so prejemali placebo v kombinaciji s karboplatinom in paklitakselom ali nabpaklitakselom.
Urothelial cancer 
Urotelijski rak
In this study, disease did not get worse for 5.1 months on average in patients taking Keytruda combination, 3.2 months in patients taking Keytruda alone and 5.0 months in patients taking other standard treatments. 
V tej študiji se bolezen ni poslabšala povprečno 5,1 meseca pri bolnikih, ki so prejemali zdravilo Keytruda v kombinaciji s kemoterapijo, 3,2 meseca pri bolnikih, ki so prejemali zdravilo Keytruda kot samostojno zdravilo, in 5,0 meseca pri bolnikih, ki so prejemali druga standardna zdravljenja.
For the other cancers, Keytruda is only used on its own. 
Pri drugih vrstah raka se zdravilo Keytruda uporablja le kot samostojno zdravilo.
Keytruda partially or completely clears cancer cells in classical Hodgkin lymphoma that has not improved or had returned after treatment with brentuximab vedotin, with or without an autologous stem cell transplantation. 
Zdravilo Keytruda skupaj z avtologno presaditvijo matičnih celic ali brez nje delno ali popolnoma uniči rakave celice pri klasičnem Hodgkinovem limfomu, ki se po zdravljenju z brentuksimabom vedotinom ni izboljšal ali se je po tovrstnem zdravljenju ponovil.
In a study of 616 patients with non-squamous NSCLC that had spread, 69% of patients taking Keytruda with pemetrexed and platinum chemotherapy were alive at 11 months, compared with less than half of patients who had only pemetrexed and platinum chemotherapy. 
V študiji pri 616 bolnikih z neploščatoceličnim nedrobnoceličnim pljučnim rakom, ki se je razširil, je 11 mesecev živelo 69 % bolnikov, ki so jemali zdravilo Keytruda skupaj s kemoterapijo s pemetreksedom in platino, in manj kot polovica bolnikov, ki so prejemali samo kemoterapijo s pemetreksedom in platino.
Keytruda is effective at improving survival or delaying the worsening of disease in patients with advanced cancers or cancers that have spread or come back. 
Zdravilo Keytruda učinkovito izboljšuje preživetje ali odloži poslabšanje bolezni pri bolnikih z napredovalimi rakavimi obolenji ali rakavimi obolenji, ki so se razširila ali ponovila.
In a study of 861 patients with renal cell carcinoma, patients given Keytruda in combination with an already authorised medicine for renal cell carcinoma, axitinib, lived for around 15 months without their disease getting worse, compared with 11 months for patients who received treatment with another renal cell carcinoma medicine, sunitinib, which was used as a control treatment. 
V študiji pri 861 bolnikih z rakom ledvičnih celic so bolniki, ki so prejemali zdravilo Keytruda v kombinaciji z že odobrenim zdravilom za zdravljenje raka ledvičnih celic, aksitinibom, živeli približno 15 mesecev brez poslabšanja bolezni v primerjavi z 11 meseci pri bolnikih, ki so se zdravili z drugim zdravilom za zdravljenje raka ledvičnih celic, sunitinibom, ki je bilo uporabljeno kot kontrolno zdravilo.
Before starting treatment, patients with NSCLC, previously untreated urothelial cancer or HNSCC should have tests to check their levels of PD-L1. 
Pred začetkom zdravljenja je treba pri bolnikih z nedrobnoceličnim pljučnim rakom, predhodno nezdravljenim urotelijskim rakom ali ploščatoceličnim rakom glave in vratu s preiskavami preveriti ravni beljakovine PD-L1.
In some cancers, it is only given to patients whose tumours produce high levels of a protein known as PD-L1. 
Pri nekaterih vrstah rakavih obolenj se daje samo bolnikom, pri katerih tumorji tvorijo večje količine beljakovine PD-L1.
Keytruda is also effective in delaying worsening of the disease and improving survival in patients with NSCLC that tested positive for the PD-L1 protein. 
Zdravilo Keytruda je učinkovito tudi pri odlogu poslabšanja bolezni in izboljšanju preživetja bolnikov z nedrobnoceličnim pljučnim rakom, ki so pozitivni na beljakovino PD-L1.
How does Keytruda work? 
Kako zdravilo Keytruda deluje?
Another study in 882 patients with HNSCC showed that Keytruda alone or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy is effective at prolonging patients' lives when HNSCC tests positive for a certain level of PD-L1. 
Druga študija pri 882 bolnikih s ploščatoceličnim rakom glave in vratu je pokazala, da je zdravilo Keytruda kot samostojno zdravilo ali v kombinaciji s kemoterapijo s platino in 5-fluoroacilom (5-FU) učinkovito pri podaljševanju življenja bolnikov, pri katerih so bili testi za določeno raven beljakovine
Keytruda improves survival of patients with urothelial cancer. 
Zdravilo Keytruda izboljša preživetje bolnikov z urotelijskim rakom.
Keytruda is given as an infusion (drip) into a vein. 
Zdravilo Keytruda se daje z infundiranjem (kapalno infuzijo) v veno.
Keytruda was more effective in patients who tested strongly for PD-L1, with these patients living for 15 months on average, 5 months of which without their disease worsening. 
Zdravilo Keytruda je bilo učinkovitejše pri bolnikih, pri katerih so bile s preiskavo ugotovljene večje količine beljakovine PD-L1, saj so ti bolniki v povprečju živeli 15 mesecev, od tega pet mesecev brez poslabšanja bolezni.
Keytruda is also effective in preventing melanoma from coming back in patients who have had surgery. 
Zdravilo Keytruda je učinkovito tudi pri preprečevanju ponovitve melanoma pri bolnikih, pri katerih je bil opravljen kirurški poseg.
How is Keytruda used? 
Kako se zdravilo Keytruda uporablja?
• renal cell carcinoma (a type of kidney cancer). 
• raka ledvičnih celic (vrste raka ledvic).
Patients treated with Keytruda lived for up to 5.6 months without their disease getting worse compared with 2.8 months with ipilimumab. 
Bolniki, zdravljeni z zdravilom Keytruda, so živeli do 5,6 meseca brez poslabšanja bolezni v primerjavi z 2,8 meseca v skupini z ipilimumabom.
Patients treated with Keytruda lived on average around 10 months compared with around 7 months with the other cancer medicines. 
Bolniki, zdravljeni z zdravilom Keytruda, so v povprečju živeli približno deset mesecev v primerjavi s približno sedem mesecev pri bolnikih, ki so prejemali druga zdravila za zdravljenje raka.
In a study of 495 patients, patients treated with Keytruda who had high levels of PD-L1 lived on average for 11.6 months while those taking standard cancer treatments lived for 6.6 months. 
V študiji, ki je zajela 495 bolnikov, so bolniki, zdravljeni z zdravilom Keytruda, pri katerih so bile s preiskavo ugotovljene večje količine beljakovine PD-L1, v povprečju živeli 11,6 meseca, bolniki, ki so prejemali standardna zdravila za zdravljenje raka, pa 6,6 meseca.
The side effects of Keytruda are mostly related to the activity of the immune system, which may cause inflammation of body organs and tissues and can be serious, although most side effects resolve with appropriate treatment or on stopping Keytruda. 
Povzročijo lahko vnetje telesnih organov in tkiv ter so lahko resni, vendar je večino neželenih učinkov mogoče odpraviti z ustreznim zdravljenjem ali prekinitvijo zdravljenja z zdravilom Keytruda.
Keytruda is also effective in improving survival of patients with head and neck squamous cell carcinoma (HNSCC) that had spread or come back. 
Zdravilo Keytruda je učinkovito tudi pri izboljšanju preživetja bolnikov s ploščatoceličnim rakom glave in vratu, ki se je razširil ali ponovil.
• a cancer affecting the head and neck known as head and neck squamous cell carcinoma (HNSCC), 
• urotelijskega raka, tj. raka sečnega mehurja in sečil; • raka, ki prizadene glavo in vrat, imenovanega ploščatocelični rak glave in vratu;
In addition, patients who had Keytruda treatment lived on average for 8.8 months without the disease getting worse compared with 4.9 months for patients who were not given Keytruda. 
Poleg tega so bolniki, ki so jemali zdravilo Keytruda, brez poslabšanja bolezni v povprečju živeli 8,8 meseca, bolniki, ki tega zdravila niso prejemali, pa 4,9 meseca.
• classical Hodgkin lymphoma, a cancer of the white blood cells, 
• nedrobnoceličnega pljučnega raka, tj. vrste pljučnega raka; • klasičnega Hodgkinovega limfoma, tj. raka belih krvnih celic;